Skip to content

FLAVIOLA Health Study

Impact of Dietary Flavanols on Vascular Health in a General Population of Healthy Middle-aged Europeans: a Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01799005
Acronym
FHS
Enrollment
100
Registered
2013-02-26
Start date
2013-02-28
Completion date
2014-08-31
Last updated
2015-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Health

Keywords

flavanols, diet, endothelial function, blood pressure, FLAVIOLA

Brief summary

Atherosclerosis progressively occurs with increasing age in the general population. So far most dietary intervention studies with flavanols were performed over short time frames and in small groups of young healthy and older patients with manifest cardiovascular disease, respectively. Vascular health is defined as absence of vascular disease and the presence of optimal parameters that determine the development and progression of arteriosclerosis (endothelial function, blood pressure, plasma lipids, and glucose). It is not clear whether flavanols can improve parameters of vascular health, most importantly endothelial function, when given repetitively to healthy middle aged and which factors affect the efficacy of flavanol interventions.

Interventions

DIETARY_SUPPLEMENTFlavanol (410 mg)
DIETARY_SUPPLEMENTControl (no flavanols)

Sponsors

Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* male, age 35-60 years, healthy * female, age 35-60 years, healthy

Exclusion criteria

* diabetes mellitus, acute inflammation, arrhythmia, active malignancy, terminal renal failure, signs, symptoms or medication indicative of manifest cardiovascular disease (CAD, PAD, CVD)

Design outcomes

Primary

MeasureTime frame
Endothelial functionTime points: day 0 [baseline], and day 30 each 0 and 2h.

Secondary

MeasureTime frame
Blood pressureTime points: day 0 [baseline], and day 30 each 0 and 2h.
GlucoseTime points: day 0 [baseline], and day 30 each 0 and 2h.
Plasma lipidsTime points: day 0 [baseline], and day 30 each 0 and 2h.

Other

MeasureTime frame
Flavanol metabolitesday 0 [baseline], and day 30 each 0 and 2h
Microvascular functionTime points: day 0 [baseline], and day 30 each 0 and 2h.
MicroparticlesTime points: day 0 [baseline], and day 30 each 0 and 2h.
Dietary patternTime points: day 0 [baseline] and day 30
Vascular stiffnessTime points: day 0 [baseline], and day 30 each 0 and 2h.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026